Can pharmaceutical companies continue to fight the long-lasting battle of new drug research and development?

When it comes to new drug research and development, many people have the impression of "burning money" It is true that it is not easy to develop a new drug It requires a lot of money, talents and sufficient time and energy Looking back on the innovation process of China's pharmaceutical industry, it has gone through the development from imitation to original, and is moving forward towards the innovation power However, due to the late start, compared with other countries, there are many deficiencies in new drug research and development in China First of all, the development of R & D innovation needs huge financial support, while most of China's pharmaceutical enterprises are small-scale and mainly focus on generic pharmaceutical production, and lack of operating profit is difficult to help enterprises carry out meaningful new drug R & D work Secondly, there are few medical talents in China After all, medicine is a complex subject It takes a lot of time to study it However, there are still some gaps between the development of medicine in China and the international level Therefore, it is urgent to inject new impetus into this cause by cultivating talents After that, the core competitiveness among pharmaceutical enterprises is insufficient The author understands that in China, the competition strategy among pharmaceutical enterprises is often based on price competition, which further weakens the profit space of enterprises Although low price competition can bring some benefits to enterprises, it is not a long-term plan, but it will make enterprises stagnate in the long run In order to speed up the innovation and research and development of drugs by local pharmaceutical enterprises, the state is also taking measures, and the release of a series of medical reform policies is a good proof For example, on April 19, 2017, the Ministry of human resources and social security issued the notice on Soliciting Opinions and suggestions on establishing and improving the dynamic adjustment mechanism of drug catalog of basic medical insurance, industrial injury insurance and maternity insurance, which is intended to meet the needs of clinical medication in time and promote pharmaceutical innovation by establishing the dynamic adjustment mechanism of drug catalog The aim of the state is to improve the concentration of the pharmaceutical industry through policies, to eliminate a group of weak enterprises through market mechanism, to improve the profitability of the industry, and to improve the innovation level of the industry, so as to cultivate a group of pharmaceutical enterprises with international competitiveness In addition, enterprises are actively responding to national policies and carrying out innovation and R & D as much as possible The author understands that by the end of 2017, 55 new drugs (chemical 1.1 + biological 1) have been approved for clinical use, including 26 chemical drugs and 29 biological drugs Looking at the data over the years, the number of clinical approval documents for new drugs approved by local enterprises is increasing year by year In addition, in January this year, some innovative drug R & D enterprises, such as Zejing pharmaceutical, Kaifeng Pharmaceutical, Fuhong Hanlin, etc., received financing, and the amount was above 100 million yuan It seems that domestic pharmaceutical companies are increasing their efforts to make further breakthroughs in new drug research and development in 2018 From the current situation of research and development of domestic pharmaceutical enterprises, there are probably these phenomena Most innovative pharmaceutical enterprises are concentrated in the Yangtze River Delta In fact, as early as the late 19th century, China's pharmaceutical industry cluster has been formed in the Yangtze River Delta At the beginning of the 21st century, with the reform and opening up, international capital gradually converged to the Yangtze River Delta At present, the Yangtze River Delta has formed an integrated pharmaceutical industry construction with Shanghai as the main axis and Jiangsu and Zhejiang as the deep hinterland Second, young enterprises are gradually emerging This society needs young blood, as well as new forces in new drug research and development It is reported that with the deepening of new technologies and concepts in the pharmaceutical industry, such as artificial intelligence, big data, black technology, etc., the clinical progress of innovative drugs approved by emerging enterprises continues to advance, and research and development driven small pharmaceutical enterprises are favored by investment institutions Third, the research and development of new drugs are mostly concentrated in the field of tumor and cancer China has a large number of cancer patients, and new cancer cases account for 1 / 4 of the world, which is actually a large market Although the country is speeding up the review and approval of imported drugs, it will take some time to be listed in China Therefore, this gives domestic pharmaceutical companies an opportunity to develop new drugs before the imported drugs go on the market in China, perhaps to occupy more market share In general, the environment for new drug research and development in China is improving, and pharmaceutical enterprises are also striving for innovation Although we all know the difficulty and risk of new drug research and development, I think that innovation is the mainstream Since we choose this road, pharmaceutical enterprises should take every step steadily After all, this is a long-lasting war, with high investment and high return Whoever can persist will laugh later.